Open an account

IRIDEX

IRIX · NASDAQ

$0.755−$0.015 (−1.95%)TodayMarket closed ·
Prev close $0.77

About IRIX

IRIDEX Corp. engages in developing, manufacturing, and marketing medical systems, delivery devices, and consumable instrumentation for the ophthalmology market. The company is headquartered in Mountain View, California and currently employs 93 full-time employees. The firm is developing, manufacturing, and marketing versatile laser-based medical systems, delivery devices and consumable instrumentation. Its MicroPulse Technology and Endpoint Management Technology are used for the treatment of glaucoma and retina disorders. Its laser consoles product consists of Glaucoma, Medical Retina and Surgical Retina. Its glaucoma console line is the Cyclo G6 laser system with MicroPulse technology. Its surgical-retina product line includes its OcuLight TX and OcuLight SLx laser photocoagulation systems. Its medical-retina product line includes its portable IQ 532 and IQ 577 laser systems. Its laser probe products include Glaucoma and Surgical Retina. Probes used in its glaucoma product line include its patented single-use delivery devices-MicroPulse P3, G-Probe, and G-Probe Illuminate. Probes used in its surgical retina product line include its family of single-use EndoProbe handpieces.

Employees
93
Headquarters
Mountain View, California
Listed
Feb 16, 1996
Sector
Health Care
Industry
Health Care Equipment & Supplies
Website
iridex.com

IRIX key statistics

Market cap
13.26M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
1.09M
Volume
37.28K
Open price
$0.77
High today
$0.78
Low today
$0.7501
52 Week high
$1.65
52 Week low
$0.607

IRIDEX (IRIX) at a glance

As of Oct 20, 2026, IRIDEX (IRIX) shares are priced at $0.755, giving the company a market cap of 13.26M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.7501 and $0.78. The current price is 0.7% above the day's low and 3.2% below its high.

Volume so far is 37.28K shares, below the average of 1.09M shares a day.

Over the past year IRIDEX has ranged from $0.607 to $1.65, and now sits 14% of the way up that range.

IRIDEX met or beat analyst EPS estimates in 5 of the last 8 quarters. In Q2 FY26 it reported -$0.07 per share against an estimate of -$0.0102.

IRIX earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 5 of the last 8 quarters, by 32.8% on average.

  1. Q4 FY24: reported -$0.05 per share against an estimate of -$0.0612
  2. Q3 FY24: reported -$0.12 per share against an estimate of -$0.0918
  3. Q1 FY25: reported -$0.10 per share against an estimate of -$0.102
  4. Q2 FY25: reported -$0.06 per share against an estimate of -$0.0918
  5. Q3 FY25: reported -$0.09 per share against an estimate of -$0.0612
  6. Q4 FY25: reported -$0.01 per share against an estimate of -$0.0204
  7. Q1 FY26: reported -$0.03 per share against an estimate of -$0.0714
  8. Q2 FY26: reported -$0.07 per share against an estimate of -$0.0102

IRIX news

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Monday's After-Market Session

  • 12 Health Care Stocks Moving In Wednesday's Intraday Session

  • 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

  • Press releaseBusiness Wire

    Vicarious Surgical Announces Election of New Directors

  • 12 Health Care Stocks Moving In Tuesday's Pre-Market Session

  • Earnings Preview For Iridex

  • 12 Health Care Stocks Moving In Friday's Pre-Market Session

Similar companies

Companies in the same industry as IRIDEX

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.